PT  - JOURNAL ARTICLE
AU  - Paredes, Miguel I.
AU  - Lunn, Stephanie M.
AU  - Famulare, Michael
AU  - Frisbie, Lauren A.
AU  - Painter, Ian
AU  - Burstein, Roy
AU  - Roychoudhury, Pavitra
AU  - Xie, Hong
AU  - Bakhash, Shah A. Mohamed
AU  - Perez, Ricardo
AU  - Lukes, Maria
AU  - Ellis, Sean
AU  - Sathees, Saraswathi
AU  - Mathias, Patrick
AU  - Greninger, Alexander
AU  - Starita, Lea M.
AU  - Frazar, Chris D.
AU  - Ryke, Erica
AU  - Zhong, Weizhi
AU  - Gamboa, Luis
AU  - Threlkeld, Machiko
AU  - Lee, Jover
AU  - Nickerson, Deborah A.
AU  - Bates, Daniel L.
AU  - Hartman, Matthew E.
AU  - Haugen, Eric
AU  - Nguyen, Truong N.
AU  - Richards, Joshua D.
AU  - Rodriguez, Jacob L.
AU  - Stamatoyannopoulos, John A.
AU  - Thorland, Eric
AU  - Melly, Geoff
AU  - Dykema, Philip E.
AU  - MacKellar, Drew C.
AU  - Gray, Hannah K.
AU  - Singh, Avi
AU  - Peterson, JohnAric MoonDance
AU  - Russell, Denny
AU  - Torres, Laura Marcela
AU  - Lindquist, Scott
AU  - Bedford, Trevor
AU  - Allen, Krisandra J.
AU  - Oltean, Hanna N.
TI  - Associations between SARS-CoV-2 variants and risk of COVID-19 hospitalization among confirmed cases in Washington State: a retrospective cohort study
AID  - 10.1101/2021.09.29.21264272
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.29.21264272
4099  - http://medrxiv.org/content/early/2021/09/30/2021.09.29.21264272.short
4100  - http://medrxiv.org/content/early/2021/09/30/2021.09.29.21264272.full
AB  - Background The COVID-19 pandemic is now dominated by variant lineages; the resulting impact on disease severity remains unclear. Using a retrospective cohort study, we assessed the risk of hospitalization following infection with nine variants of concern or interest (VOC/VOI).Methods Our study includes individuals with positive SARS-CoV-2 RT-PCR in the Washington Disease Reporting System and with available viral genome data, from December 1, 2020 to July 30, 2021. The main analysis was restricted to cases with specimens collected through sentinel surveillance. Using a Cox proportional hazards model with mixed effects, we estimated hazard ratios (HR) for the risk of hospitalization following infection with a VOC/VOI, adjusting for age, sex, and vaccination status.Findings Of the 27,814 cases, 23,170 (83.3%) were sequenced through sentinel surveillance, of which 726 (3.1%) were hospitalized due to COVID-19. Higher hospitalization risk was found for infections with Gamma (HR 3.17, 95% CI 2.15-4.67), Beta (HR: 2.97, 95% CI 1.65–5.35), Delta (HR: 2.30, 95% CI 1.69-3.15), and Alpha (HR 1.59, 95% CI 1.26–1.99) compared to infections with an ancestral lineage. Following VOC infection, unvaccinated patients show a similar higher hospitalization risk, while vaccinated patients show no significant difference in risk, both when compared to unvaccinated, ancestral lineage cases.Interpretation Infection with a VOC results in a higher hospitalization risk, with an active vaccination attenuating that risk. Our findings support promoting hospital preparedness, vaccination, and robust genomic surveillance.Competing Interest StatementALG reports funding for central testing lab from Abbott and research funding from Merck and Gilead. All other authors declare no competing interests.Funding StatementT.B. is a Pew Biomedical Scholar and is supported by NIH grant no. R35 GM119774, P.R. is supported by a CFAR New Investigator Award (NIH AI027757). The Seattle Flu Study is run through the Brotman Baty Institute for Precision Medicine and funded by Gates Ventures, the private office of Bill Gates. This work was supported by CDC BAA contract 75D30121C10982. Employees of the Institute for Disease Modeling (MF, RB) received no specific funding for the project. Computational analyses for UW Virology data were supported by Fred Hutch Scientific Computing (NIH ORIP grant S10OD028685). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Washington State Institutional Review Board designated this study as exempt. Sequencing and analysis of samples from the Seattle Flu Study was approved by the Institutional Review Board (IRB) at the University of Washington (protocol STUDY00006181). Sequencing of remnant clinical specimens at UW Virology Lab was approved by the University of Washington Institutional Review Board (protocol STUDY00000408). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests to access these data are handled by the Washington Department of Health